Quest Diagnostics (NYSE: DGX), announced on Wednesday that its board of directors declared a quarterly cash dividend of USD0.53 per share.
The dividend is payable on 29 January 2020 to shareholders of record of Quest Diagnostics common stock on 14 January 2020.
Quest Diagnostics is a provider of diagnostic information services. Derived from the world's largest database of clinical lab results, the company's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviours and improve health care management.
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
Everest Medicines expands I-MAB investment
Perrigo Announces Quarterly Dividend
Ridgetech reports net income of USD10.20m in fiscal year 2025
Sanofi finalizes acquisition of Blueprint Medicines to expand rare disease and immunology portfolio
Perrigo to divest Dermacosmetics business for up to EUR327m
CVS Health declares quarterly dividend USD0.665 per share
Lilly declares dividend of USD1.50 for Q3
Bavarian Nordic sells US Priority Review Voucher for USD160m